Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in rheumatoid arthritis patients with interstitial lung disease - Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in RA-ILD

Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University0 个研究点目标入组 34 人开始时间: 2013年2月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•A patient who has any of the following conditions will be excluded from this study. 1. When a patient has acute exacerbation of interstitial lung disease (when a patient has acutely progressive bilateral lung infiltration and is considered to be inappropriate for the study entry by the attending physician) 2. When a patient has pulmonary hemorrhage 3. When a patient is considered to require positive pressure ventilation (positive pressure ventilation via endotracheal intubation or noninvasive positive pressure ventilation) 4. When a patient is diagnosed as having active respiratory infection or drug-induced pneumonia 5. In a case with ILD of UIP or NSIP pattern, when tacrolimus is contraindicated or a patient has ever treated with tacrolimus for ILD before 6. In a case with ILD of OP pattern, both MTX and tacrolimus are contraindicated or a patient has ever treated by either MTX or tacrolimus for ILD 7. When a patient is considered to require prednisolone with the dose of more than 0.5 mg/kg/day 8. When a patient has moderate or severe pulmonary hypertension or heart failure 9. When a patient has collagen vascular disease other than rheumatoid arthritis (Sjogren's syndrome is permissible) 10. When a patient has severe organ involvement other than interstitial lung disease 11. When a patient is considered as ineligible for this study for any reason by the attending physician

发起方

Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University